Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer

Authors: Ping Wei, Nu Zhang, Ye Xu, Xinxiang Li, Debing Shi, Yuwei Wang, Dawei Li, Sanjun Cai

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

We have previously demonstrated an aberrant overexpression of the microtubule-associated protein TPX2 in colon cancer using a genome-wide gene expression profiling analysis. Here, we aim to investigate its expression pattern, clinical significance, and biological function in colon cancer.

Methods

TPX2 expression was analyzed in human colon cancer cell lines and tumor samples. The effect of TPX2 on cell proliferation, tumorigenesis, and metastasis was examined in vitro and in vivo.

Results

TPX2 was overexpressed in 129 of the 203 (60.8%) colon cancer metastatic lesions, with the expression being significantly higher than that in primary cancerous tissue and normal colon mucosa. Overexpression of TPX2 was significantly associated with clinical staging, vessel invasion, and metastasis. In survival analyses, patients with TPX2 overexpression had worse overall survival and metastasis free survival, suggesting that deregulation of TPX2 may contribute to the metastasis of colon cancer. Consistent with this, suppression of TPX2 expression inhibited proliferation and tumorigenicity of colon cancer cells both in vitro and in vivo. Strikingly, we found that TPX2 knockdown significantly attenuated the migration and invasion ability of colon cancer cells, which was further shown to be mechanistically associated with AKT-mediated MMP2 activity.

Conclusions

These findings suggest that TPX2 plays an important role in promoting tumorigenesis and metastasis of human colon cancer, and may represent a novel prognostic biomarker and therapeutic target for the disease.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
2.
Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K, Shim YM: Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007, 22: 699-704. 10.1007/s00384-006-0218-2.CrossRefPubMed
3.
Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P: European colorectal metastases treatment group:towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006, 42: 2212-2221. 10.1016/j.ejca.2006.04.012.CrossRefPubMed
4.
Yoo PS, Lopez-Soler RI, Longo WE, Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006, 6: 202-207. 10.3816/CCC.2006.n.036.CrossRefPubMed
5.
Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J ClinOncol. 2005, 23: 9243-9249. 10.1200/JCO.2005.07.740.CrossRef
6.
Zhang Y, Heidebrecht H, Rott A, Schlegelberger B, Parwaresch R: Assignment of human proliferation associated p100 gene (C20orf1) to human chromosome band 20q11.2 by in situ hybridization. Cytogenet Cell Genet. 1999, 84: 182-183. 10.1159/000015251.CrossRefPubMed
7.
Wittmann T, Boleti H, Antony C, Karsenti E, Vernos I: Localization of the kinesin-like protein Xklp2 to spindle poles requires a leucine zipper, a microtubule-associated protein, and dynein. J Cell Biol. 1999, 143: 673-685.CrossRef
8.
Tulu US, Fagerstrom C, Ferenz NP, Wadsworth P: Molecular requirements for kinetochore-associated microtubule formation in mammalian cells. CurrBiol. 2006, 16: 536-541.CrossRef
9.
Gruss OJ, Wittmann M, Yokoyama H, Pepperkok R, Kufer T, Silljé H, Karsenti E, Mattaj IW, Vernos I: Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nat Cell Biol. 2002, 4: 871-879. 10.1038/ncb870.CrossRefPubMed
10.
11.
Gruss OJ, Carazo-Salas RE, Schatz CA, Guarguaglini G, Kast J, Wilm M, Le Bot N, Vernos I, Karsenti E, Mattaj IW: Ran induces spindle assembly by reversing the inhibitory effect of importin α on TPX2 activity. Cell. 2001, 104: 83-93. 10.1016/S0092-8674(01)00193-3.CrossRefPubMed
12.
Kufer TA, Sillje HH, Korner R, Gruss OJ, Meraldi P, Nigg EA: Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol. 2002, 158: 617-623. 10.1083/jcb.200204155.PubMedCentralCrossRefPubMed
13.
Bayliss R, Sardon T, Vernos I, Conti E: Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell. 2003, 12: 851-862. 10.1016/S1097-2765(03)00392-7.CrossRefPubMed
14.
Ozlü N, Srayko M, Kinoshita K, Habermann B, O’toole ET, Müller-Reichert T, Schmalz N, Desai A, Hyman AA: An essential function of the C. elegansortholog of TPX2 is to localize activated aurora A kinase to mitotic spindles. Dev Cell. 2005, 9: 237-248. 10.1016/j.devcel.2005.07.002.CrossRefPubMed
15.
Stewart S, Fang G: Anaphase-promoting complex/cyclosome controls the stability of TPX2 during mitotic exit. Mol Cell Biol. 2005, 25: 10516-10527. 10.1128/MCB.25.23.10516-10527.2005.PubMedCentralCrossRefPubMed
16.
Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA: High resolution genomic profiles of human lung cancer. ProcNatlAcadSci U S A. 2005, 102: 9625-9630. 10.1073/pnas.0504126102.CrossRef
17.
Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H, Von Hoff DD: Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. Clin Cancer Res. 2009, 15: 6519-6528. 10.1158/1078-0432.CCR-09-0077.PubMedCentralCrossRefPubMed
18.
Smith LT, Mayerson J, Nowak NJ, Suster D, Mohammed N, Long S, Auer H, Jones S, McKeegan C, Young G, Bos G, Plass C, Morrison C: 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer. 2006, 45: 957-966. 10.1002/gcc.20354.CrossRefPubMed
19.
Li D, Peng Z, Tang H, Wei P, Kong X, Yan D, Huang F, Li Q, Le X, Li Q, Xie K: KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin Cancer Res. 2011, 17: 3558-3368. 10.1158/1078-0432.CCR-10-2729.PubMedCentralCrossRefPubMed
20.
Li D, Wei P, Peng Z, Huang C, Tang H, Jia Z, Cui J, Le X, Huang S, Xie K: The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res. 2013, 19: 62-72. 10.1158/1078-0432.CCR-12-1588.PubMedCentralCrossRefPubMed
21.
Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D, Vernetti L, Schurdak M, Wang J, Fesik SW: Identification of Ras-related nuclear protein, targeting protein for xenopuskinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 2007, 67: 4390-4398. 10.1158/0008-5472.CAN-06-4132.CrossRefPubMed
22.
Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T: Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res. 2010, 16: 2518-2528. 10.1158/1078-0432.CCR-09-2214.CrossRefPubMed
23.
Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N, Guo S, Feng X, Su K, Mao Y, Cheng S, Gao Y: Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res. 2006, 12: 1121-1127. 10.1158/1078-0432.CCR-05-1766.CrossRefPubMed
24.
Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R: Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009, 2: 702-711. 10.1158/1940-6207.CAPR-09-0084.CrossRef
25.
Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A: AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006, 25: 4831-4839. 10.1038/sj.onc.1209494.CrossRefPubMed
26.
Chowdhury A, Chowdhury S, Tsai MY: A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma. 2012, 53: 462-471. 10.3109/10428194.2011.619018.CrossRefPubMed
27.
Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002, 2: 563-572. 10.1038/nrc865.CrossRefPubMed
28.
Sieber O, Heinimann K, Tomlinson I: Genomic stability and tumorigenesis. Semin Cancer Biol. 2005, 15: 61-66. 10.1016/j.semcancer.2004.09.005.CrossRefPubMed
29.
Carney BK, Caruso Silva V, Cassimeris L: The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. Cytoskeleton (Hoboken). 2012, 69: 278-289. 10.1002/cm.21024.CrossRef
30.
Aguirre-Portolés C, Bird AW, Hyman A, Cañamero M, Pérez de Castro I, Malumbres M: Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012, 72: 1518-1528. 10.1158/0008-5472.CAN-11-1971.CrossRefPubMed
31.
Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006, 42: 2212-2221. 10.1016/j.ejca.2006.04.012.CrossRefPubMed
32.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25: 9-34. 10.1007/s10555-006-7886-9.CrossRefPubMed
33.
Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015.PubMedCentralCrossRefPubMed
34.
Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. BiochimBiophysActa. 2012, 1825: 29-36.
35.
Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001, 7: 2396-2404.PubMed
36.
Cheng JC, Chou CH, Kuo ML, Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 2006, 25: 7009-7018. 10.1038/sj.onc.1209706.CrossRefPubMed
37.
Chien CS, Shen KH, Huang JS, Ko SC, Shih YW: Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem. 2010, 333: 169-180. 10.1007/s11010-009-0217-z.CrossRefPubMed
Metadata
Title
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer
Authors
Ping Wei
Nu Zhang
Ye Xu
Xinxiang Li
Debing Shi
Yuwei Wang
Dawei Li
Sanjun Cai
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-313

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed

Research

Autologous transplantation of adipose-derived stromal cells ameliorates ventilator-induced lung injury in rats

Research

SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion

Research

The role of human umbilical cord tissue-derived mesenchymal stromal cells (UCX®) in the treatment of inflammatory arthritis

Research

Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer

Research

Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits